| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 106 | 2026 | 949 | 9.750 |
Why?
|
| T-Lymphocytes | 126 | 2026 | 1716 | 9.620 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 105 | 2024 | 1267 | 8.630 |
Why?
|
| T-Lymphocytes, Cytotoxic | 92 | 2018 | 510 | 7.940 |
Why?
|
| Herpesvirus 4, Human | 109 | 2025 | 643 | 7.570 |
Why?
|
| Epstein-Barr Virus Infections | 48 | 2025 | 293 | 5.750 |
Why?
|
| Lymphoproliferative Disorders | 42 | 2022 | 217 | 5.080 |
Why?
|
| Lymphoma | 32 | 2025 | 328 | 4.640 |
Why?
|
| Receptors, Antigen, T-Cell | 38 | 2025 | 499 | 4.570 |
Why?
|
| Bone Marrow Transplantation | 69 | 2021 | 589 | 4.060 |
Why?
|
| Adoptive Transfer | 37 | 2019 | 235 | 3.950 |
Why?
|
| Hodgkin Disease | 35 | 2022 | 308 | 3.440 |
Why?
|
| Graft vs Host Disease | 51 | 2024 | 684 | 2.950 |
Why?
|
| Hematologic Neoplasms | 22 | 2024 | 312 | 2.910 |
Why?
|
| Immunotherapy | 41 | 2025 | 758 | 2.780 |
Why?
|
| Antigens, CD19 | 24 | 2024 | 188 | 2.730 |
Why?
|
| Lymphoma, Non-Hodgkin | 15 | 2019 | 163 | 2.030 |
Why?
|
| Leukemia | 26 | 2024 | 374 | 1.870 |
Why?
|
| Neoplasms | 29 | 2024 | 2955 | 1.850 |
Why?
|
| Cytomegalovirus | 25 | 2024 | 257 | 1.740 |
Why?
|
| Transplantation, Homologous | 59 | 2024 | 666 | 1.650 |
Why?
|
| Humans | 399 | 2026 | 130483 | 1.650 |
Why?
|
| Genetic Therapy | 28 | 2022 | 718 | 1.580 |
Why?
|
| Gene Transfer Techniques | 27 | 2015 | 344 | 1.570 |
Why?
|
| Viral Matrix Proteins | 20 | 2018 | 108 | 1.560 |
Why?
|
| Transplantation Conditioning | 30 | 2022 | 326 | 1.550 |
Why?
|
| Genetic Vectors | 35 | 2022 | 899 | 1.510 |
Why?
|
| Virus Diseases | 15 | 2023 | 284 | 1.500 |
Why?
|
| Antigens, Neoplasm | 21 | 2026 | 397 | 1.460 |
Why?
|
| Lymphocyte Transfusion | 12 | 2021 | 56 | 1.390 |
Why?
|
| Recombinant Fusion Proteins | 20 | 2018 | 693 | 1.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2023 | 850 | 1.350 |
Why?
|
| Burkitt Lymphoma | 7 | 2023 | 132 | 1.290 |
Why?
|
| Herpesviridae Infections | 14 | 2013 | 140 | 1.240 |
Why?
|
| Tissue Donors | 19 | 2021 | 500 | 1.240 |
Why?
|
| Retroviridae | 19 | 2022 | 182 | 1.170 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2014 | 197 | 1.160 |
Why?
|
| Nasopharyngeal Neoplasms | 10 | 2014 | 57 | 1.130 |
Why?
|
| Gangliosides | 3 | 2025 | 71 | 1.130 |
Why?
|
| Cytomegalovirus Infections | 8 | 2024 | 220 | 1.110 |
Why?
|
| Tumor Virus Infections | 11 | 2006 | 131 | 1.070 |
Why?
|
| Multiple Myeloma | 11 | 2021 | 186 | 1.010 |
Why?
|
| Transplants | 3 | 2021 | 38 | 0.950 |
Why?
|
| Antigens, Viral | 21 | 2019 | 392 | 0.940 |
Why?
|
| Cytokines | 20 | 2023 | 1342 | 0.910 |
Why?
|
| Neuroblastoma | 10 | 2025 | 543 | 0.900 |
Why?
|
| Antibodies, Monoclonal | 20 | 2015 | 982 | 0.890 |
Why?
|
| Adenoviridae | 28 | 2023 | 583 | 0.880 |
Why?
|
| Immunosuppressive Agents | 17 | 2021 | 665 | 0.860 |
Why?
|
| Lymphoma, Follicular | 1 | 2024 | 32 | 0.830 |
Why?
|
| Child | 115 | 2025 | 26101 | 0.830 |
Why?
|
| Lymphoma, B-Cell | 10 | 2024 | 146 | 0.830 |
Why?
|
| Interleukin-2 | 19 | 2014 | 237 | 0.820 |
Why?
|
| Lymphocyte Activation | 36 | 2018 | 632 | 0.810 |
Why?
|
| Data Mining | 1 | 2024 | 65 | 0.810 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 | 2020 | 176 | 0.800 |
Why?
|
| Leukopenia | 1 | 2023 | 45 | 0.770 |
Why?
|
| Caspase 9 | 9 | 2015 | 76 | 0.760 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 140 | 0.750 |
Why?
|
| Cell- and Tissue-Based Therapy | 11 | 2024 | 152 | 0.740 |
Why?
|
| Virus Activation | 7 | 2015 | 86 | 0.730 |
Why?
|
| Adolescent | 97 | 2025 | 20737 | 0.730 |
Why?
|
| Recurrence | 30 | 2023 | 1472 | 0.730 |
Why?
|
| Lymphocytes | 12 | 2024 | 348 | 0.730 |
Why?
|
| Male | 136 | 2026 | 64488 | 0.720 |
Why?
|
| Killer Cells, Natural | 12 | 2023 | 342 | 0.720 |
Why?
|
| Genetic Markers | 20 | 2003 | 591 | 0.710 |
Why?
|
| Child, Preschool | 79 | 2025 | 14945 | 0.680 |
Why?
|
| Interleukin-15 | 7 | 2024 | 103 | 0.680 |
Why?
|
| Living Donors | 5 | 2016 | 111 | 0.680 |
Why?
|
| Virus Replication | 4 | 2022 | 606 | 0.680 |
Why?
|
| Immunity, Cellular | 8 | 2016 | 193 | 0.680 |
Why?
|
| Transplantation Immunology | 7 | 2011 | 40 | 0.670 |
Why?
|
| T-Cell Antigen Receptor Specificity | 11 | 2021 | 55 | 0.670 |
Why?
|
| Antigen-Presenting Cells | 6 | 2018 | 123 | 0.660 |
Why?
|
| DNA Virus Infections | 4 | 2017 | 22 | 0.650 |
Why?
|
| Adult | 93 | 2026 | 31179 | 0.640 |
Why?
|
| Antiviral Agents | 8 | 2024 | 806 | 0.640 |
Why?
|
| Leukemia, Myeloid, Acute | 17 | 2021 | 574 | 0.630 |
Why?
|
| Adenoviridae Infections | 6 | 2013 | 76 | 0.620 |
Why?
|
| Female | 127 | 2026 | 70388 | 0.610 |
Why?
|
| Clinical Trials as Topic | 17 | 2021 | 1123 | 0.610 |
Why?
|
| Stem Cell Transplantation | 12 | 2020 | 231 | 0.600 |
Why?
|
| Genetic Engineering | 2 | 2015 | 160 | 0.590 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 6 | 2014 | 59 | 0.590 |
Why?
|
| Anemia | 1 | 2023 | 352 | 0.590 |
Why?
|
| Lymphocyte Depletion | 15 | 2024 | 122 | 0.590 |
Why?
|
| Treatment Outcome | 51 | 2026 | 12843 | 0.590 |
Why?
|
| Vaccination | 1 | 2024 | 1046 | 0.570 |
Why?
|
| Sarcoma, Ewing | 2 | 2019 | 120 | 0.560 |
Why?
|
| Melanoma | 4 | 2014 | 924 | 0.560 |
Why?
|
| Transplantation, Autologous | 24 | 2022 | 260 | 0.560 |
Why?
|
| B-Lymphocytes | 16 | 2015 | 510 | 0.540 |
Why?
|
| Antineoplastic Agents | 14 | 2018 | 1790 | 0.540 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2011 | 544 | 0.540 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2017 | 103 | 0.530 |
Why?
|
| Ki-1 Antigen | 5 | 2020 | 31 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 1268 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2022 | 1316 | 0.510 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 44 | 0.500 |
Why?
|
| Alemtuzumab | 10 | 2024 | 89 | 0.500 |
Why?
|
| Phosphoproteins | 6 | 2012 | 454 | 0.500 |
Why?
|
| Graft Rejection | 6 | 2020 | 558 | 0.490 |
Why?
|
| Receptors, Antigen | 3 | 2016 | 33 | 0.490 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2014 | 144 | 0.460 |
Why?
|
| Leukocytes, Mononuclear | 11 | 2023 | 354 | 0.460 |
Why?
|
| Antigens, CD | 10 | 2015 | 411 | 0.460 |
Why?
|
| Immunophenotyping | 17 | 2023 | 332 | 0.460 |
Why?
|
| Transgenes | 5 | 2015 | 320 | 0.450 |
Why?
|
| Middle Aged | 60 | 2026 | 28438 | 0.450 |
Why?
|
| Cells, Cultured | 25 | 2020 | 2903 | 0.450 |
Why?
|
| Cell Culture Techniques | 9 | 2014 | 277 | 0.440 |
Why?
|
| Lymphoma, T-Cell | 4 | 2024 | 67 | 0.430 |
Why?
|
| Infant | 43 | 2025 | 13234 | 0.430 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 699 | 0.420 |
Why?
|
| DNA, Viral | 15 | 2011 | 452 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2020 | 640 | 0.410 |
Why?
|
| Animals | 56 | 2024 | 33862 | 0.410 |
Why?
|
| Young Adult | 29 | 2024 | 10010 | 0.410 |
Why?
|
| Genes, Transgenic, Suicide | 8 | 2015 | 48 | 0.400 |
Why?
|
| Epitopes | 9 | 2020 | 321 | 0.400 |
Why?
|
| Antibodies, Neoplasm | 8 | 2008 | 55 | 0.400 |
Why?
|
| Cytotoxicity, Immunologic | 18 | 2017 | 271 | 0.400 |
Why?
|
| Salvage Therapy | 5 | 2021 | 175 | 0.390 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 48 | 0.390 |
Why?
|
| Cancer Vaccines | 6 | 2014 | 189 | 0.380 |
Why?
|
| Cell Proliferation | 21 | 2018 | 2469 | 0.380 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 208 | 0.370 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2012 | 465 | 0.370 |
Why?
|
| Stem Cell Research | 3 | 2016 | 5 | 0.370 |
Why?
|
| Cell Line | 25 | 2022 | 2566 | 0.370 |
Why?
|
| Cyclophosphamide | 10 | 2024 | 435 | 0.360 |
Why?
|
| Protein Kinases | 1 | 2013 | 317 | 0.350 |
Why?
|
| Graft vs Leukemia Effect | 4 | 2021 | 39 | 0.340 |
Why?
|
| Bone Marrow | 7 | 2021 | 319 | 0.340 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.330 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 813 | 0.330 |
Why?
|
| Viral Load | 10 | 2019 | 406 | 0.330 |
Why?
|
| Liver Transplantation | 6 | 2013 | 1126 | 0.330 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 156 | 0.330 |
Why?
|
| Bone Marrow Cells | 6 | 2021 | 243 | 0.330 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 16 | 0.330 |
Why?
|
| Tumor Escape | 6 | 2018 | 62 | 0.330 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 26 | 0.330 |
Why?
|
| Aged | 37 | 2026 | 20918 | 0.320 |
Why?
|
| Epitopes, T-Lymphocyte | 8 | 2014 | 126 | 0.320 |
Why?
|
| Muscle Proteins | 1 | 2013 | 404 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2012 | 499 | 0.320 |
Why?
|
| Lentivirus | 3 | 2018 | 81 | 0.320 |
Why?
|
| Cell Transformation, Viral | 5 | 2006 | 96 | 0.320 |
Why?
|
| Granulomatous Disease, Chronic | 3 | 2018 | 70 | 0.320 |
Why?
|
| Immunocompromised Host | 11 | 2014 | 309 | 0.310 |
Why?
|
| Leukemia, Hairy Cell | 5 | 1993 | 16 | 0.310 |
Why?
|
| Leukemia, Myeloid | 9 | 2006 | 80 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2021 | 129 | 0.300 |
Why?
|
| Dendritic Cells | 12 | 2009 | 437 | 0.300 |
Why?
|
| Remission Induction | 11 | 2020 | 303 | 0.300 |
Why?
|
| Histocompatibility | 6 | 2011 | 42 | 0.300 |
Why?
|
| Glioblastoma | 4 | 2017 | 374 | 0.300 |
Why?
|
| Mice | 36 | 2024 | 18243 | 0.290 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 5176 | 0.290 |
Why?
|
| Myeloablative Agonists | 2 | 2021 | 23 | 0.290 |
Why?
|
| Unrelated Donors | 5 | 2021 | 71 | 0.280 |
Why?
|
| Myocardium | 1 | 2013 | 863 | 0.280 |
Why?
|
| Postoperative Complications | 11 | 2011 | 3109 | 0.280 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 3712 | 0.280 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2008 | 3 | 0.280 |
Why?
|
| Immunity | 4 | 2021 | 180 | 0.280 |
Why?
|
| DNA Viruses | 3 | 2017 | 30 | 0.270 |
Why?
|
| Fever | 1 | 2010 | 307 | 0.270 |
Why?
|
| Leukocyte Common Antigens | 5 | 2023 | 84 | 0.270 |
Why?
|
| Tissue Transplantation | 2 | 2005 | 10 | 0.270 |
Why?
|
| Tacrolimus | 4 | 2021 | 102 | 0.270 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 1998 | 15 | 0.270 |
Why?
|
| Mice, SCID | 14 | 2015 | 585 | 0.270 |
Why?
|
| Sarcoma | 2 | 2024 | 218 | 0.270 |
Why?
|
| Flow Cytometry | 15 | 2015 | 771 | 0.270 |
Why?
|
| Retrospective Studies | 28 | 2024 | 17550 | 0.260 |
Why?
|
| Time Factors | 20 | 2021 | 6200 | 0.260 |
Why?
|
| Prognosis | 11 | 2021 | 4880 | 0.250 |
Why?
|
| Lymphocyte Subsets | 4 | 2017 | 39 | 0.250 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2020 | 159 | 0.250 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 239 | 0.250 |
Why?
|
| Herpesvirus 6, Human | 4 | 2017 | 53 | 0.250 |
Why?
|
| Combined Modality Therapy | 14 | 2024 | 1226 | 0.250 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2008 | 124 | 0.240 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 4 | 2011 | 33 | 0.240 |
Why?
|
| Oncogenic Viruses | 1 | 2006 | 22 | 0.240 |
Why?
|
| Transplantation | 2 | 2013 | 25 | 0.240 |
Why?
|
| Interferon-gamma | 12 | 2013 | 549 | 0.240 |
Why?
|
| Carcinoma | 4 | 2014 | 283 | 0.240 |
Why?
|
| CD28 Antigens | 7 | 2024 | 76 | 0.230 |
Why?
|
| Virus Latency | 5 | 2008 | 63 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 2 | 2026 | 742 | 0.230 |
Why?
|
| Transduction, Genetic | 12 | 2014 | 277 | 0.230 |
Why?
|
| Neomycin | 4 | 2000 | 36 | 0.230 |
Why?
|
| Genome, Viral | 1 | 2006 | 161 | 0.230 |
Why?
|
| CD40 Ligand | 4 | 2011 | 65 | 0.230 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 758 | 0.230 |
Why?
|
| Histocompatibility Testing | 8 | 2011 | 107 | 0.230 |
Why?
|
| Methotrexate | 4 | 2021 | 338 | 0.220 |
Why?
|
| Peptides | 4 | 2018 | 705 | 0.220 |
Why?
|
| Antigens, CD34 | 5 | 2001 | 97 | 0.220 |
Why?
|
| Vidarabine | 6 | 2024 | 91 | 0.220 |
Why?
|
| HLA Antigens | 6 | 2019 | 226 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2019 | 57 | 0.220 |
Why?
|
| Roseolovirus Infections | 3 | 2012 | 29 | 0.220 |
Why?
|
| CD3 Complex | 7 | 2010 | 94 | 0.220 |
Why?
|
| Chronic Disease | 9 | 2024 | 1233 | 0.220 |
Why?
|
| Cell Line, Transformed | 12 | 2014 | 159 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 37 | 0.210 |
Why?
|
| Antilymphocyte Serum | 5 | 2006 | 44 | 0.210 |
Why?
|
| Hematopoiesis | 6 | 2023 | 212 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2023 | 57 | 0.210 |
Why?
|
| Transfection | 4 | 2011 | 961 | 0.210 |
Why?
|
| Immunoglobulin kappa-Chains | 3 | 2016 | 29 | 0.210 |
Why?
|
| Membrane Glycoproteins | 4 | 2013 | 410 | 0.210 |
Why?
|
| Drug Resistance | 7 | 2009 | 239 | 0.200 |
Why?
|
| Virus Integration | 3 | 2015 | 37 | 0.200 |
Why?
|
| Survival Analysis | 6 | 2018 | 1491 | 0.200 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 894 | 0.200 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 1169 | 0.200 |
Why?
|
| Quinazolines | 1 | 2024 | 177 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2026 | 192 | 0.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 91 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 11 | 2011 | 1455 | 0.190 |
Why?
|
| Adenovirus Infections, Human | 3 | 2009 | 60 | 0.190 |
Why?
|
| Proteome | 1 | 2025 | 290 | 0.190 |
Why?
|
| Guidelines as Topic | 2 | 2016 | 199 | 0.190 |
Why?
|
| Cellular Senescence | 2 | 2024 | 217 | 0.190 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 1325 | 0.180 |
Why?
|
| Hematologic Diseases | 4 | 2020 | 82 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 10 | 2013 | 978 | 0.180 |
Why?
|
| Fetal Blood | 4 | 2010 | 177 | 0.180 |
Why?
|
| Allografts | 3 | 2021 | 218 | 0.180 |
Why?
|
| Risk Factors | 18 | 2017 | 10953 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 86 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 993 | 0.180 |
Why?
|
| Apoptosis | 6 | 2024 | 1832 | 0.180 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 27 | 0.180 |
Why?
|
| Avian Proteins | 1 | 2001 | 9 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2002 | 26 | 0.180 |
Why?
|
| Antigens, Surface | 2 | 2001 | 112 | 0.180 |
Why?
|
| Interleukin-7 | 2 | 2014 | 46 | 0.180 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 25 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 107 | 0.170 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 18 | 0.170 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 50 | 0.170 |
Why?
|
| Treatment Failure | 1 | 2022 | 349 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 213 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 298 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2024 | 315 | 0.170 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 106 | 0.170 |
Why?
|
| Blood Proteins | 1 | 2001 | 140 | 0.170 |
Why?
|
| Natural Killer T-Cells | 1 | 2022 | 90 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 5 | 2011 | 332 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2105 | 0.160 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.160 |
Why?
|
| Cell Engineering | 1 | 2020 | 21 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 97 | 0.160 |
Why?
|
| Donor Selection | 2 | 2012 | 57 | 0.160 |
Why?
|
| Rituximab | 4 | 2022 | 170 | 0.160 |
Why?
|
| Thiotepa | 1 | 2020 | 17 | 0.160 |
Why?
|
| Antigens | 3 | 2013 | 104 | 0.160 |
Why?
|
| Recombinant Proteins | 13 | 2003 | 1318 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1223 | 0.150 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2016 | 212 | 0.150 |
Why?
|
| Immunologic Memory | 5 | 2014 | 196 | 0.150 |
Why?
|
| Plasmids | 2 | 2018 | 447 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 84 | 0.150 |
Why?
|
| Feasibility Studies | 7 | 2022 | 812 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 1996 | 31 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 64 | 0.150 |
Why?
|
| United States | 12 | 2023 | 11871 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 68 | 0.150 |
Why?
|
| Research Design | 3 | 2014 | 715 | 0.140 |
Why?
|
| Antigens, CD20 | 3 | 2006 | 45 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 1610 | 0.140 |
Why?
|
| Immunotoxins | 3 | 2003 | 21 | 0.140 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 472 | 0.140 |
Why?
|
| Interleukin-12 | 3 | 2004 | 124 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 4 | 2008 | 107 | 0.140 |
Why?
|
| Antigen Presentation | 6 | 2014 | 111 | 0.140 |
Why?
|
| Leukemia, Lymphoid | 5 | 1999 | 99 | 0.140 |
Why?
|
| Methylprednisolone | 2 | 1995 | 94 | 0.140 |
Why?
|
| Organic Chemicals | 5 | 2015 | 58 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 25 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2018 | 116 | 0.130 |
Why?
|
| Leukemia, B-Cell | 2 | 2010 | 25 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2019 | 228 | 0.130 |
Why?
|
| Infusions, Intravenous | 5 | 2010 | 535 | 0.130 |
Why?
|
| Neoplasms, Experimental | 3 | 2014 | 201 | 0.130 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 792 | 0.130 |
Why?
|
| Ricin | 2 | 1994 | 9 | 0.130 |
Why?
|
| Gene Expression | 8 | 2017 | 1487 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 331 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2009 | 60 | 0.130 |
Why?
|
| Stem Cells | 3 | 2016 | 712 | 0.130 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 228 | 0.130 |
Why?
|
| Age Factors | 4 | 2011 | 2838 | 0.130 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 73 | 0.130 |
Why?
|
| Survival Rate | 6 | 2017 | 2127 | 0.130 |
Why?
|
| Acute Disease | 9 | 2011 | 1149 | 0.130 |
Why?
|
| Biomarkers | 6 | 2016 | 3388 | 0.120 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 681 | 0.120 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2014 | 73 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 144 | 0.120 |
Why?
|
| Bone Marrow Purging | 7 | 2003 | 34 | 0.120 |
Why?
|
| Antigens, Differentiation | 2 | 1995 | 63 | 0.120 |
Why?
|
| Quality of Life | 3 | 2021 | 2082 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 126 | 0.120 |
Why?
|
| Tissue Banks | 2 | 2019 | 27 | 0.120 |
Why?
|
| Membrane Lipids | 1 | 1995 | 30 | 0.120 |
Why?
|
| Glycolipids | 1 | 1995 | 33 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 84 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 266 | 0.110 |
Why?
|
| Clinical Protocols | 5 | 1996 | 230 | 0.110 |
Why?
|
| Prednisone | 2 | 2014 | 239 | 0.110 |
Why?
|
| Medulloblastoma | 2 | 2011 | 381 | 0.110 |
Why?
|
| Immunoglobulin M | 2 | 1995 | 211 | 0.110 |
Why?
|
| Internationality | 1 | 2016 | 129 | 0.110 |
Why?
|
| Perforin | 1 | 2015 | 24 | 0.110 |
Why?
|
| K562 Cells | 6 | 2014 | 97 | 0.110 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 15 | 0.110 |
Why?
|
| Viruses | 2 | 2014 | 117 | 0.110 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 20 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2018 | 295 | 0.110 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 23 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2021 | 1101 | 0.110 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 290 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 41 | 0.110 |
Why?
|
| Lymphocyte Count | 5 | 2017 | 119 | 0.110 |
Why?
|
| Basigin | 2 | 2006 | 12 | 0.110 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1991 | 10 | 0.110 |
Why?
|
| Siblings | 3 | 2015 | 201 | 0.110 |
Why?
|
| RNA, Messenger | 7 | 2009 | 2560 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 13 | 0.100 |
Why?
|
| Prospective Studies | 10 | 2024 | 6450 | 0.100 |
Why?
|
| Etanercept | 1 | 2014 | 44 | 0.100 |
Why?
|
| Genomics | 1 | 2022 | 1620 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2014 | 32 | 0.100 |
Why?
|
| Thalidomide | 1 | 2014 | 38 | 0.100 |
Why?
|
| Genome, Human | 2 | 2018 | 1318 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2013 | 33 | 0.100 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1994 | 41 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 49 | 0.100 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 17 | 0.100 |
Why?
|
| Connectin | 1 | 2013 | 28 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 68 | 0.100 |
Why?
|
| Aphthovirus | 1 | 2013 | 3 | 0.100 |
Why?
|
| Interferon-alpha | 2 | 1993 | 239 | 0.100 |
Why?
|
| RNA Viruses | 1 | 2013 | 32 | 0.100 |
Why?
|
| Steroids | 2 | 2006 | 169 | 0.100 |
Why?
|
| Amino Acid Sequence | 9 | 2013 | 2406 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 91 | 0.100 |
Why?
|
| Societies, Medical | 3 | 2019 | 796 | 0.100 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2013 | 27 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 186 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 903 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 2083 | 0.090 |
Why?
|
| Granulocytes | 3 | 1991 | 69 | 0.090 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2013 | 32 | 0.090 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 61 | 0.090 |
Why?
|
| Graft Survival | 6 | 2012 | 459 | 0.090 |
Why?
|
| Incidence | 7 | 2019 | 3326 | 0.090 |
Why?
|
| Adenoviruses, Human | 5 | 2017 | 97 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 97 | 0.090 |
Why?
|
| Whole-Body Irradiation | 4 | 2006 | 61 | 0.090 |
Why?
|
| Peptide Fragments | 5 | 2011 | 687 | 0.090 |
Why?
|
| CD27 Ligand | 1 | 2011 | 5 | 0.090 |
Why?
|
| Graft vs Host Reaction | 1 | 1991 | 11 | 0.090 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1994 | 182 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 300 | 0.090 |
Why?
|
| Clone Cells | 3 | 2008 | 152 | 0.090 |
Why?
|
| Azacitidine | 1 | 2011 | 52 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2007 | 1210 | 0.090 |
Why?
|
| Allergy and Immunology | 1 | 2011 | 30 | 0.090 |
Why?
|
| Coculture Techniques | 4 | 2014 | 232 | 0.090 |
Why?
|
| Infant, Newborn | 8 | 2018 | 8518 | 0.090 |
Why?
|
| Phenotype | 10 | 2018 | 4479 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2011 | 62 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 68 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 85 | 0.080 |
Why?
|
| Osteosarcoma | 2 | 2015 | 276 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 784 | 0.080 |
Why?
|
| Enzyme Induction | 2 | 2014 | 92 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2010 | 62 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 189 | 0.080 |
Why?
|
| Primary Myelofibrosis | 1 | 2011 | 53 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2008 | 566 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2907 | 0.080 |
Why?
|
| Receptors, Fc | 1 | 2010 | 29 | 0.080 |
Why?
|
| Guillain-Barre Syndrome | 2 | 2018 | 33 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2010 | 36 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 155 | 0.080 |
Why?
|
| Haplotypes | 4 | 2015 | 515 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 41 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2011 | 223 | 0.080 |
Why?
|
| Single-Chain Antibodies | 1 | 2010 | 42 | 0.080 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2009 | 20 | 0.080 |
Why?
|
| Cell Division | 7 | 2004 | 719 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2024 | 5081 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 95 | 0.080 |
Why?
|
| Informed Consent | 4 | 2016 | 349 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 1076 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 82 | 0.080 |
Why?
|
| Busulfan | 2 | 2023 | 48 | 0.070 |
Why?
|
| Anemia, Aplastic | 2 | 2006 | 61 | 0.070 |
Why?
|
| Mice, Inbred NOD | 3 | 2020 | 301 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 60 | 0.070 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 381 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2023 | 358 | 0.070 |
Why?
|
| Molecular Sequence Data | 9 | 2013 | 3487 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 4 | 2008 | 454 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2012 | 447 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 765 | 0.070 |
Why?
|
| Peptide Library | 3 | 2018 | 56 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 382 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 233 | 0.070 |
Why?
|
| Kanamycin Kinase | 3 | 1998 | 15 | 0.070 |
Why?
|
| DNA, Cruciform | 1 | 2008 | 18 | 0.070 |
Why?
|
| Erythrocytes | 2 | 1979 | 188 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2298 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2011 | 320 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2011 | 523 | 0.070 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 46 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2024 | 410 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 666 | 0.070 |
Why?
|
| Lung Diseases | 2 | 2004 | 395 | 0.070 |
Why?
|
| CD5 Antigens | 3 | 2010 | 33 | 0.060 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 20 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2014 | 805 | 0.060 |
Why?
|
| Capsid Proteins | 1 | 2007 | 148 | 0.060 |
Why?
|
| Biopsy | 3 | 2020 | 1248 | 0.060 |
Why?
|
| HLA-A Antigens | 4 | 2011 | 33 | 0.060 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 1986 | 1 | 0.060 |
Why?
|
| Kinetics | 4 | 2011 | 1087 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 100 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 175 | 0.060 |
Why?
|
| Societies, Scientific | 2 | 2016 | 24 | 0.060 |
Why?
|
| Blood Platelet Disorders | 1 | 1986 | 14 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1986 | 29 | 0.060 |
Why?
|
| Mandatory Reporting | 1 | 2006 | 20 | 0.060 |
Why?
|
| Pregnancy, Multiple | 1 | 1986 | 44 | 0.060 |
Why?
|
| Puerperal Disorders | 1 | 1986 | 46 | 0.060 |
Why?
|
| DNA | 5 | 2008 | 1407 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2006 | 55 | 0.060 |
Why?
|
| Regeneration | 1 | 1988 | 227 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2023 | 147 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2008 | 254 | 0.060 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2005 | 33 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1401 | 0.060 |
Why?
|
| Cystitis | 2 | 2003 | 47 | 0.060 |
Why?
|
| Cell Separation | 5 | 2012 | 220 | 0.060 |
Why?
|
| Algorithms | 2 | 2010 | 1676 | 0.060 |
Why?
|
| Pancytopenia | 2 | 2018 | 40 | 0.060 |
Why?
|
| Cytarabine | 2 | 2022 | 98 | 0.060 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2003 | 34 | 0.060 |
Why?
|
| Vaccines | 1 | 2010 | 384 | 0.050 |
Why?
|
| Histocompatibility Antigens | 2 | 2007 | 16 | 0.050 |
Why?
|
| Antibody Formation | 3 | 2006 | 227 | 0.050 |
Why?
|
| Cell Survival | 5 | 2007 | 836 | 0.050 |
Why?
|
| Hyponatremia | 1 | 1985 | 71 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2004 | 110 | 0.050 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 207 | 0.050 |
Why?
|
| Caspases | 1 | 2005 | 153 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 1998 | 63 | 0.050 |
Why?
|
| Virulence | 1 | 2005 | 272 | 0.050 |
Why?
|
| Acetates | 1 | 2024 | 78 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2024 | 25 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2017 | 145 | 0.050 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 42 | 0.050 |
Why?
|
| Safety | 4 | 2006 | 214 | 0.050 |
Why?
|
| HLA-A2 Antigen | 3 | 2011 | 25 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2003 | 24 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 100 | 0.050 |
Why?
|
| Genes, Viral | 2 | 2001 | 155 | 0.050 |
Why?
|
| Species Specificity | 2 | 2014 | 477 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 274 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2004 | 170 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2005 | 155 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 343 | 0.050 |
Why?
|
| Complement Activation | 1 | 2003 | 50 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 528 | 0.050 |
Why?
|
| Models, Biological | 4 | 2013 | 1386 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 33 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2003 | 43 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 26 | 0.050 |
Why?
|
| Organophosphonates | 1 | 2002 | 21 | 0.050 |
Why?
|
| Physicians | 1 | 2009 | 635 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 4671 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 203 | 0.050 |
Why?
|
| Cytosine | 1 | 2002 | 57 | 0.050 |
Why?
|
| Vaccines, Subunit | 1 | 2003 | 74 | 0.050 |
Why?
|
| Killer Cells, Lymphokine-Activated | 3 | 1991 | 8 | 0.050 |
Why?
|
| Heterografts | 1 | 2023 | 192 | 0.050 |
Why?
|
| Antibody Specificity | 2 | 2001 | 164 | 0.050 |
Why?
|
| Dasatinib | 1 | 2022 | 51 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 218 | 0.050 |
Why?
|
| Certification | 1 | 2023 | 68 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Ischemia | 1 | 1985 | 358 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 43 | 0.050 |
Why?
|
| CD4 Antigens | 1 | 2002 | 52 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2001 | 13 | 0.040 |
Why?
|
| Germany | 1 | 2021 | 59 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2011 | 3679 | 0.040 |
Why?
|
| Asia | 1 | 2022 | 125 | 0.040 |
Why?
|
| Genes, MDR | 1 | 2001 | 6 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 481 | 0.040 |
Why?
|
| Half-Life | 1 | 2001 | 148 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 233 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2001 | 366 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 2105 | 0.040 |
Why?
|
| Myeloid Cells | 2 | 2017 | 112 | 0.040 |
Why?
|
| Cell Movement | 1 | 2004 | 870 | 0.040 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 39 | 0.040 |
Why?
|
| HL-60 Cells | 2 | 2014 | 31 | 0.040 |
Why?
|
| Chemokines, C | 1 | 2000 | 10 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 234 | 0.040 |
Why?
|
| Oncogenes | 1 | 2001 | 163 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 560 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 17 | 0.040 |
Why?
|
| Disease Progression | 3 | 2017 | 2204 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 43 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 238 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2013 | 11 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 61 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 178 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 708 | 0.040 |
Why?
|
| Smoking | 1 | 1985 | 919 | 0.040 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2003 | 230 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 374 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2004 | 393 | 0.040 |
Why?
|
| Podophyllotoxin | 2 | 1999 | 6 | 0.040 |
Why?
|
| Monocytes | 2 | 2012 | 337 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 174 | 0.040 |
Why?
|
| Growth Inhibitors | 2 | 1989 | 35 | 0.040 |
Why?
|
| Hemagglutination | 1 | 1979 | 7 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2015 | 1017 | 0.040 |
Why?
|
| National Health Programs | 2 | 2010 | 20 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 3640 | 0.040 |
Why?
|
| Philadelphia Chromosome | 2 | 2008 | 41 | 0.040 |
Why?
|
| Cell-Free System | 2 | 1989 | 62 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1999 | 10 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2001 | 170 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 511 | 0.040 |
Why?
|
| Kidney | 1 | 1985 | 1278 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 548 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interferon Type I | 2 | 1990 | 120 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 1999 | 72 | 0.040 |
Why?
|
| Fibronectins | 1 | 1999 | 100 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2011 | 4679 | 0.040 |
Why?
|
| Drug Approval | 1 | 2018 | 46 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 29 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 441 | 0.030 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1168 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 80 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2018 | 77 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 154 | 0.030 |
Why?
|
| Restriction Mapping | 3 | 1997 | 167 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 1997 | 45 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 822 | 0.030 |
Why?
|
| HIV | 1 | 1999 | 176 | 0.030 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 46 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1991 | 32 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 716 | 0.030 |
Why?
|
| Gene Editing | 1 | 2020 | 235 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 41 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2002 | 800 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 58 | 0.030 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1997 | 42 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 4715 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 318 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 256 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1997 | 182 | 0.030 |
Why?
|
| Rats | 4 | 2009 | 3381 | 0.030 |
Why?
|
| Hypertension | 1 | 1985 | 1349 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 173 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 246 | 0.030 |
Why?
|
| Oocyte Donation | 1 | 2016 | 5 | 0.030 |
Why?
|
| Leukocytes | 1 | 1978 | 208 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 2016 | 28 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1998 | 173 | 0.030 |
Why?
|
| Chimera | 1 | 2016 | 80 | 0.030 |
Why?
|
| Nuclear Family | 1 | 1996 | 50 | 0.030 |
Why?
|
| CD2 Antigens | 2 | 2012 | 8 | 0.030 |
Why?
|
| X Chromosome | 1 | 1997 | 328 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1995 | 36 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1997 | 463 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1995 | 100 | 0.030 |
Why?
|
| Portal Vein | 1 | 1995 | 85 | 0.030 |
Why?
|
| Globins | 1 | 1995 | 20 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 3834 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2006 | 92 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 203 | 0.030 |
Why?
|
| Mycoses | 1 | 1996 | 109 | 0.030 |
Why?
|
| Mesna | 1 | 1994 | 6 | 0.030 |
Why?
|
| Moloney murine leukemia virus | 1 | 1994 | 17 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 319 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 725 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2014 | 159 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 136 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 351 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 45 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2016 | 195 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1991 | 68 | 0.030 |
Why?
|
| Cyclosporine | 2 | 2006 | 131 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2011 | 307 | 0.030 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 248 | 0.030 |
Why?
|
| Liver Diseases | 1 | 1997 | 380 | 0.020 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2013 | 20 | 0.020 |
Why?
|
| Age of Onset | 1 | 2015 | 596 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2013 | 62 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1991 | 248 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 369 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2013 | 31 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1930 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 109 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 14 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 654 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 724 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1996 | 322 | 0.020 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 151 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2003 | 37 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2013 | 158 | 0.020 |
Why?
|
| HIV Infections | 1 | 2005 | 2037 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2002 | 18 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 775 | 0.020 |
Why?
|
| Karyotyping | 2 | 1997 | 309 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3806 | 0.020 |
Why?
|
| Chromatin | 1 | 2015 | 504 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 255 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1211 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 233 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 13 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1991 | 16 | 0.020 |
Why?
|
| Registries | 2 | 2011 | 1607 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 22 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 769 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 13 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 37 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 442 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 1991 | 16 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 440 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1991 | 64 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 40 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 57 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 133 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 92 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 58 | 0.020 |
Why?
|
| Immune Evasion | 1 | 2011 | 38 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2010 | 47 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 163 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1826 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2002 | 358 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 276 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 129 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 11 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 3 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 19 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 53 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 81 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 64 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 137 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2005 | 71 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 48 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 2005 | 155 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1990 | 97 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 1990 | 33 | 0.020 |
Why?
|
| Growth Substances | 1 | 1989 | 99 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1990 | 123 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 262 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 263 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 17 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1990 | 110 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 390 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1290 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 19 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 157 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 237 | 0.020 |
Why?
|
| Base Sequence | 4 | 1994 | 2750 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 500 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 832 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 162 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 529 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 2336 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 193 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 808 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 266 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 184 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1988 | 56 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 385 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 371 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 126 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2008 | 20 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 592 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1990 | 347 | 0.020 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2007 | 15 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1991 | 598 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 361 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1988 | 330 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 643 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 140 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2007 | 281 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2001 | 521 | 0.020 |
Why?
|
| Homeostasis | 1 | 1991 | 715 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 1991 | 717 | 0.020 |
Why?
|
| Life Tables | 1 | 2006 | 25 | 0.020 |
Why?
|
| Premedication | 1 | 1986 | 39 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 70 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2014 | 0.020 |
Why?
|
| Twins | 1 | 1986 | 71 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2564 | 0.020 |
Why?
|
| Vincristine | 1 | 1987 | 188 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1107 | 0.020 |
Why?
|
| Mutation | 2 | 2015 | 6119 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 39 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 695 | 0.020 |
Why?
|
| Brain | 2 | 2011 | 3164 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 48 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 2 | 1998 | 196 | 0.010 |
Why?
|
| Biological Products | 1 | 1988 | 142 | 0.010 |
Why?
|
| Accreditation | 1 | 2006 | 86 | 0.010 |
Why?
|
| Electronic Mail | 1 | 2006 | 41 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 374 | 0.010 |
Why?
|
| Lung | 1 | 1994 | 1547 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 266 | 0.010 |
Why?
|
| Receptors, OX40 | 1 | 2005 | 9 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1987 | 288 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2005 | 6 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1985 | 110 | 0.010 |
Why?
|
| Spleen | 1 | 2006 | 257 | 0.010 |
Why?
|
| Polylysine | 1 | 2004 | 11 | 0.010 |
Why?
|
| Dimerization | 1 | 2005 | 138 | 0.010 |
Why?
|
| Postpartum Hemorrhage | 1 | 1986 | 111 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1987 | 358 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 85 | 0.010 |
Why?
|
| Infection Control | 1 | 2006 | 162 | 0.010 |
Why?
|
| Fibroblasts | 2 | 2004 | 855 | 0.010 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2004 | 25 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 135 | 0.010 |
Why?
|
| Serotyping | 1 | 2004 | 172 | 0.010 |
Why?
|
| Integrins | 1 | 2004 | 90 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2004 | 104 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 19 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 424 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1448 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 52 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 105 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2004 | 88 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 54 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1601 | 0.010 |
Why?
|
| Feces | 1 | 2007 | 721 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 15 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3750 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 144 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 10 | 0.010 |
Why?
|
| Internet | 1 | 2006 | 420 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1986 | 426 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 186 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2002 | 50 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 319 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 320 | 0.010 |
Why?
|
| Syndrome | 1 | 1985 | 1160 | 0.010 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 2002 | 3 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 64 | 0.010 |
Why?
|
| Blood | 1 | 2002 | 99 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 2002 | 13 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1376 | 0.010 |
Why?
|
| Respirovirus Infections | 1 | 2002 | 19 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 157 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 54 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 82 | 0.010 |
Why?
|
| Carrier State | 1 | 2002 | 81 | 0.010 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| Hemocyanins | 2 | 1992 | 23 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 144 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 218 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 300 | 0.010 |
Why?
|
| Family | 1 | 2003 | 585 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 101 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 391 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6809 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 623 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 362 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 341 | 0.010 |
Why?
|
| Immune Sera | 1 | 1979 | 55 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 586 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 498 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1979 | 56 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 599 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 700 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1978 | 8 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1978 | 54 | 0.010 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 8 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 236 | 0.010 |
Why?
|
| Liver Failure | 1 | 1999 | 99 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1685 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1997 | 98 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1997 | 26 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1997 | 185 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 1999 | 308 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 742 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 332 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 1995 | 20 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1999 | 491 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1995 | 77 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 101 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1995 | 418 | 0.010 |
Why?
|
| Self Concept | 1 | 1995 | 158 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 227 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1964 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 1999 | 376 | 0.010 |
Why?
|
| Pregnancy | 1 | 1986 | 7407 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1993 | 220 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 118 | 0.010 |
Why?
|
| Survivors | 1 | 1995 | 344 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 190 | 0.010 |
Why?
|
| Mollusca | 1 | 1992 | 8 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 956 | 0.010 |
Why?
|
| CD58 Antigens | 1 | 1991 | 7 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 1991 | 11 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1991 | 122 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 255 | 0.010 |
Why?
|
| Vimentin | 1 | 1990 | 59 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1991 | 126 | 0.000 |
Why?
|
| Lymphocyte Cooperation | 1 | 1990 | 9 | 0.000 |
Why?
|
| Plasma Cells | 1 | 1990 | 54 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 150 | 0.000 |
Why?
|
| Cell Adhesion Molecules | 1 | 1991 | 224 | 0.000 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1989 | 34 | 0.000 |
Why?
|
| Cognition | 1 | 1995 | 811 | 0.000 |
Why?
|
| Echocardiography | 1 | 1995 | 1126 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 296 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1991 | 731 | 0.000 |
Why?
|
| Cricetinae | 1 | 1989 | 362 | 0.000 |
Why?
|
| Thymidine | 1 | 1988 | 49 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1989 | 291 | 0.000 |
Why?
|
| Feedback | 1 | 1988 | 147 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 1374 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1988 | 420 | 0.000 |
Why?
|